| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,210 | 1,290 | 16:52 | |
| 1,140 | 1,170 | 16:10 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.11. | Aclarion, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 20.10. | Aclarion, Inc.: Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026 | 1 | GlobeNewswire (USA) | ||
| 13.10. | Aclarion, Inc.: Aclarion to Present at the 20th Annual LD Micro Main Event | 1 | GlobeNewswire (USA) | ||
| ACLARION Aktie jetzt für 0€ handeln | |||||
| 08.10. | Aclarion, Inc.: Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment | 362 | GlobeNewswire (Europe) | New criteria fully approved at nine of eleven active sites expected to significantly accelerate enrollment paceInitial readout timing to be updated by year-end based on demonstrated Q4 enrollment... ► Artikel lesen | |
| 29.09. | Aclarion, Inc.: Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites | 1 | GlobeNewswire (USA) | ||
| 20.08. | Aclarion adds University of Arizona to Nociscan spine trial | 1 | Investing.com | ||
| 12.08. | Aclarion, Inc.: Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process | 482 | GlobeNewswire (Europe) | Patent protects the precision of MRS data capture within the target disc - a critical step in the Nociscan workflowDesigned to reduce scan time, support faster technologist onboarding and deliver... ► Artikel lesen | |
| 06.08. | Aclarion, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 04.08. | Aclarion, Inc.: Aclarion Announces Nociscan Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology | 1 | GlobeNewswire (USA) | ||
| 29.07. | Aclarion: Scan-Volumen im ersten Halbjahr 2026 um 141 % gestiegen | 3 | Investing.com Deutsch | ||
| 29.07. | Aclarion, Inc.: Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026 | 621 | GlobeNewswire (Europe) | 141% year-over-year scan volume growth in first half of 2026Reimbursement momentum in the U.K. translating into consistent scan volume growth Launched Market Access Program in partnership with PRIA... ► Artikel lesen | |
| 09.07. | Aclarion, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 07.07. | Aclarion adds Texas Spine Care Center to CLARITY trial | 1 | Investing.com | ||
| 07.07. | Aclarion erweitert CLARITY-Studie um Texas Spine Care Center | 2 | Investing.com Deutsch | ||
| 07.07. | Aclarion, Inc.: Aclarion Announces Texas Spine Care Center as New CLARITY Site | 1 | GlobeNewswire (USA) | ||
| 10.06. | Aclarion, Inc.: Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub | 2 | GlobeNewswire (USA) | ||
| 09.06. | Aclarion partners with PRIA Healthcare on market access program | 4 | Investing.com | ||
| 09.06. | Aclarion, Inc.: Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform | 451 | GlobeNewswire (Europe) | Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion's AI-driven platform for chronic low back pain. Program aims to follow successful reimbursement wins in the UK... ► Artikel lesen | |
| 08.06. | Aclarion Comments on Echo Lake News | 1 | Baystreet.ca | ||
| 08.06. | Aclarion, Inc.: Aclarion Rejects Echo Lake Capital's Unsolicited Acquisition Proposal | 893 | GlobeNewswire (Europe) | BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTUITIVE SURGICAL | 368,45 | -0,67 % | INTUITIVE SURGICAL INC - S-8, Securities to be offered to employees in employee benefit plans | ||
| UNITEDHEALTH | 313,00 | +3,99 % | AKTIEN IM FOKUS: US-Krankenversicherer geraten weiter unter Druck | NEW YORK (dpa-AFX) - Die Aktien von US-Krankenversicherern sind am Mittwoch weiter unter Druck geraten. Als Schlusslicht im Dow Jones Industrial büßten Unitedhealth 8,6 Prozent ein, womit die Aktien... ► Artikel lesen | |
| THERMO FISHER | 618,80 | -1,43 % | 65% der untersuchten FDA-Rückschläge betrafen Produktionsstätten: Die unsichtbare Hürde für Lonza, Thermo Fisher und NeuroThera | ||
| ATOSSA THERAPEUTICS | 1,570 | -2,48 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update | SEATTLE, Nov. 10, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences GAAP EPS of $0.00, revenue of $4.63M | ||
| CENTENE | 60,06 | +0,47 % | RBC raises Centene stock price target to $73 on earnings recovery | ||
| QUIDELORTHO | 7,790 | -4,09 % | QuidelOrtho Corporation: QuidelOrtho Reports Second Quarter 2026 Financial Results | ? Total revenue grew 3% reported and 2% constant currency, primarily driven by Labs and Point of Care growth ?
? Excluding China, total revenue grew 6% both as... ► Artikel lesen | |
| VERU | 2,145 | +1,66 % | Veru presents data on enobosarm for obesity treatment | ||
| TEMPEST THERAPEUTICS | 0,295 | -3,69 % | Tempest Therapeutics: Tempest Reports Third Quarter 2026 Financial Results and Provides Business Update | ||
| NANO-X IMAGING | 0,230 | -0,04 % | NANO-X IMAGING LTD: Nanox to Showcase Its Innovative Technology and Advances Across Nanox.ARC X and Nanox.AI at RSNA 2026 | ||
| FULGENT GENETICS | 22,800 | +0,88 % | Fulgent Genetics mietet neuen Standort in Massachusetts für monatlich 132.072 $ | ||
| PERSPECTIVE THERAPEUTICS | 0,657 | -7,33 % | XFRA AAJ0: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| LANTHEUS | 92,50 | -0,64 % | Lantheus Holdings, Inc.: Lantheus Presents Data from Two Pivotal Phase 3 Studies of TAUKLARIFY (Florquinitau F 18 Injection) PET Imaging in Early Alzheimer's Disease | ||
| OMNICELL | 30,000 | -1,32 % | Is This the Right Time to Retain Omnicell Stock in Your Portfolio? | ||
| AMN HEALTHCARE SERVICES | 35,600 | +13,38 % | AMN Healthcare Services, Inc.: Amn Healthcare Announces Third Quarter 2026 Results | Quarterly revenue of $717 million and adjusted EBITDA of $94 million; GAAP net income of $0.83/share and adjusted EPS of $1.16 DALLAS, Nov. 5, 2026 /PRNewswire/ -- AMN Healthcare Services, Inc. (NYSE:... ► Artikel lesen |